Shay Capital’s Roivant Sciences ROIV Stock Holding History

Shay Capital’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-38,000	Closed	-$280K	–	553
2023 Q1	$280K	Buy	+38,000	New	+$313K	0.06%	247

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PSC

Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

Shay Capital's ROIV Position: Q3 2025 in Review

Shay Capital sold out of Roivant Sciences (ROIV) in Q3 2025, closing a stake of 15,478 shares — an estimated $174K sold.

Shay Capital first reported a position in ROIV in Q1 2023 and held it in 7 quarters. The position peaked at $196K in Q2 2024. 337 funds tracked by Wall St. Rank hold ROIV as of Q3 2025.

Shay Capital reported no remaining Roivant Sciences position as of Q3 2025 after selling out during the quarter.
Shay Capital sold 15,478 Roivant Sciences shares in Q3 2025, an estimated $174K.
Shay Capital first reported a position in Roivant Sciences in Q1 2023 and held it in 7 quarters.
Shay Capital's Roivant Sciences position peaked at $196K in Q2 2024.
337 funds tracked by Wall St. Rank held Roivant Sciences as of Q3 2025.

Based on Shay Capital's 13F filing for Q3 2025, filed 14 Nov 2025.